Cardiol Therapeutics (CRDL) Issues Year-end Update on Operations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- BuzzFeed cuts 35% of workforce in restructuring move
Cardiol Therapeutics Announces Year-End 2024 Update on Operations
April 1, 2025 7:29 AM EDTReported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx" administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial
Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx" in patients
with acute myocarditis, with topline data expected in Q2 2025
CardiolRx" granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis,
which includes recurrent pericarditis
Cash and cash equivalents of $30.6 million as of December 31, 2024,
to fund operations into Q3... More
